AstraZeneca Pharma India shares fell 1.25% to ₹8,090 despite Q1 FY27 revenue rising 30% YoY to ₹682.79 crore. PAT declined 32% to ₹37.93 crore, while PBT before exceptional items fell to ₹50.99 crore. Oncology revenue grew 26% and Biopharmaceuticals rose 36%. The company also received key regulatory approvals and launched healthcare initiatives.